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Abstract
Background: A substantial prevalence of mild neurocognitive disorders has been reported in HIV, also in patients
treated with combination antiretroviral therapy (cART). This includes a new disorder that has been termed
asymptomatic neurocognitive impairment (ANI).
Discussion: ANI is identified by performance on formal neuropsychological testing that is at least 1 SD below the
mean of normative scores in at least two cognitive domains out of at least five examined in patients without
associated symptoms or evident functional impairment in daily living. While two tests are recommended to assess
each domain, only one is required to fulfill this diagnostic criterion. Unfortunately, this definition necessitates that
about 20% of the cognitively normal HIV-infected population is classified as suffering ANI. This liberal definition
raises important ethical concerns and has as well diagnostic and therapeutic implications. Since neither its
biological substrate, prognostic significance nor therapeutic implications are clearly established, we recommend
that this diagnosis be modified or applied cautiously.
Summary: The diagnoses of less severe forms of neurocognitive disorders in HIV relies on the outcomes of
neuropsychological testing, and a high proportion of HIV-infected patients with effective cART may be classified as
neurocognitively abnormal using the current criteria. The definition of ANI is not stringent, and results in
approximately 20% of the population being classified as abnormal. To us this seems an unacceptable false-positive
rate.
Please see related article: http://www.biomedcentral.com/1741-7015/9/138
Background
The introduction of combination antiretroviral therapy
(cART) for human immunodeficiency virus (HIV) has
had a substantial effect on morbidity and mortality in
the HIV-infected population. Notably, the incidence of
severe neurocognitive disorders, including AIDS demen-
tia complex (ADC), also termed HIV associated demen-
tia (HAD), has decreased markedly among HIV-infected
patients during the last 15 years [1-3].
However, the prevalence of milder neurocognitive
abnormalities detected by neuropsychological testing has
been reported to remain high, including in patients trea-
ted with cART [4-7]. In 2007, a revised classification
was proposed for HIV-related CNS impairment that
included milder forms of neurocognitive disturbance [8].
This revised nomenclature, referred to as the Frascati
criteria, established two new terms to cover milder
impairment: asymptomatic neurocognitive impairment
(ANI) and minor neurocognitive disorder (MND). Both
are defined by impairment on neuropsychological tests
compared to norms, but while the cognitive impairment
is accompanied by mild interference in daily functioning
in MND, ANI is by definition asymptomatic without
such overt interference. ANI and MND are both sub-
sumed within the broader term HIV-associated neuro-
cognitive disorders (HAND), which additionally includes
the more severe HAD [8] (Table 1).
High prevalence of ANI and MND has been reported
in several recent studies using these new Frascati cri-
teria. For example, Simioni et al found that 60% of HIV-
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infected subjects on suppressive cART and without any
subjective complaints fulfilled the criteria of ANI [6],
and 33% of patients without confounding comorbidities
were diagnosed with ANI in the CHARTER-cohort [4].
While acknowledging that symptomatic mild neurocog-
nitive impairment (MND) is a problem in some HIV-
infected patients on cART, mainly in those with a his-
tory of low CD4 cell nadir, the very high prevalence of
neurocognitive impairment in these reports does not
correspond to our impression in everyday clinical
experience. This prompted us to critically scrutinize the
basis for ANI diagnosis.
Statistical considerations
HAD is characterized by marked neurocognitive impair-
ment ascertained by neuropsychological testing out-
comes that are 2 standard deviations (SD) or greater
below demographically-related means in at least two
ability domains (attention-information processing, lan-
guage, abstraction-executive, complex perceptual motor
skills, memory, including learning and recall, simple
motor skills and sensory perceptual abilities) [8]. Unlike
HAD, ANI and MND are defined by performance at
least 1 SD below the mean of normative scores in at
least two cognitive areas; these criteria specify that at
least five of the cognitive domains are examined or
observed. If possible, at least two tests per domain are
recommended; however, this is not mandatory, in many
settings is impractical and has not been followed rigidly
in all reports [9]. If two or more tests are used per
domain not all individual tests are needed to fall below
1 SD of appropriate norms. Impairment in only one of
the tests has been sufficient in some studies [6] while
the mean results or some other aggregating method has
been used in others [4]. The latter leads to similar statis-
tical considerations as with one test performed for each
domain. As mentioned before, MND differs from ANI
in that the cognitive impairment produces at least mild
interference in daily functioning. The HAND diagnoses
are applied only if the cognitive impairment cannot be
explained by other comorbidities, though this is some-
times difficult and one report divides subjects into those
with incidental, contributing and confounding comor-
bidities - distinctions that may be arbitrary and difficult
to apply in many patients [4].
Providing normal distribution, 2.3% of a population
will perform worse than 2 SD below the mean and
15.9% below 1 SD on a given test. Thus, in each neu-
ropsychological test almost 16% of the population will
have a test result that is defined as abnormal. The prob-
ability of a test result below 1 SD in at least two tests
depends on how many tests are performed and also how
these tests intercorrelate. Despite assessing different
domains, a positive correlation between some tests of
neuropsychological performance can be presumed,
though the magnitude of this correlation is uncertain, i.
e. the probability to perform abnormally when testing
one domain is increased if the test performance of
another domain is abnormal.
Assume the tests of five domains follow a multivariate
normal distribution and that the correlations between
tests in the same domain are 0.8, while the correlations
between tests in different domains are 0 ≤ r ≤ 0.8, i.e.
the same non-negative correlation r. While the theoretic
calculation of the probability for ANI is non-trivial for
arbitrary r, it can easily be determined by simulations.
Figure 1 shows a probability plot with various correla-
tions. The probability varies between 18 and 21% with
performance worse than 1 SD below mean in one test
(or average of tests) per domain on at least two domains
of five tested (blue solid line). If more tests or domains
are assessed [4,6], the probability of an abnormal test
result will be even higher. The reality is however more
complicated, and there are likely differing correlations
between each of the tests; however, the probability will
never be lower than 16%. In fact, this corresponds well
to what has been noted in normals using these cutoffs
[4]. If more than 1 SD impairment in two tests per
Table 1 Criteria for HIV-associated neurocognitive disorders [8]
HAND HIV-associated neurocognitive disorders
ANI HIV-associated asymptomatic neurocognitive impairment
Cognitive impairment involving at least two cognitive domains (performance of at least 1 SD below the mean for norms on
neuropsychological tests)
The cognitive impairment does not interfere with everyday functioning.
MND HIV-1-associated mild neurocognitive disorder
Cognitive impairment involving at least two cognitive domains (performance of at least 1 SD below the mean for norms on
neuropsychological tests)
The cognitive impairment produces at least mild interference in daily functioning
HAD HIV-1-associated dementia (HAD)
Marked cognitive impairment involving at least two cognitive domains (performance of at least 2 SD below the mean for norms on
neuropsychological tests)
The cognitive impairment produces marked interference with day-to-day functioning
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domain are required, the probability to be diagnosed as
impaired will be lower, between 8 and 13% and if 1.5
SD are used as cut-off (Figure 1, blue dotted line), the
probability will be 4-8% to perform abnormal, with one
test per domain (Figure 1, red line).
Discussion
The diagnoses of less severe forms of HAND relies on
the outcomes of neuropsychological testing, and a high
proportion of HIV-infected patients with effective cART
may be classified as neurocognitively abnormal using the
Frascati criteria, most commonly with mild deficits, i.e.
ANI and MND. In addition to the problem that the com-
parison group in evaluating neuropsychological testing
results consists of normals who were presumably
screened for confounding conditions rather than back-
ground-matched controls tested in the same setting, the
definition of ANI is not stringent, and results in between
16 and 21% of the population being classified as abnor-
mal. To us this seems an unacceptable false-positive rate.
There are several problems with using such a gener-
ous definition. First, by exaggerating the prevalence by a
loose definition, the real extent of inapparent HIV-
related brain disease is obscured. There is little doubt
that some patients, often long-term infected and treated,
with complaints about milder memory problems and
slowness, difficulties in concentration, planning, and
multitasking suffer impaired cognitive function. Some of
these have no confounders or alternative explanations
and presumably represent development of brain injury
either before or during suppressive cART. In the latter
case, this may relate to ongoing HIV replication within
the CNS despite controlled infection in the periphery
[10]. More common may be mild neurocognitive impair-
ments as a consequence of HIV-related CNS injury in
the past, before treatment initiation. This is suggested
by the fact that low blood CD4 cell nadir is a risk factor
for neurocognitive impairment during cART [11]. How-
ever, augmenting the prevalence of these disorders by
false-positive identification of impairment confounds
both clinical trials and daily clinical management.
Second and importantly, there is an ethical dilemma
in categorizing patients that don’t have any symptoms
or complaints as neurocognitively impaired. There is no
evidence that patients with ANI are at increased risk to
develop more severe impairment or have a need of any
specific intervention. This is especially true in patients
with an ongoing effective antiretroviral treatment. An
ANI diagnosis, with uncertain relevance, may also lead
to anxiety and impact on that person’s life and
employment.
Similar considerations of early detection of neuro-
cognitive impairment are also discussed in other dis-
eases. In contrast to ANI, the definition of mild
cognitive impairment (MCI) as a precursor for Alzhei-
mer’s disease requires subjective memory complaints
in addition to impaired neurocognitive performance
[12]. In Alzheimer’s disease, advances in the under-
standing of imaging and biochemical changes occur-
ring early in the illness have improved the ability to
diagnose the disease in its early phase. Biomarkers are
now incorporated in the diagnostic criteria of Alzhei-
mer’s disease [13] and may even be useful in predicting
incipient development of Alzheimer’s disease in those
with MCI [14].
The uncertain incidence of ongoing brain injury dur-
ing antiretroviral treatment, indicates a need for a more
biologically-based and precise definition of abnormality
also in HIV-associated neurocognitive disorders. Such a
definition should preferably include objective laboratory-
based biomarkers in addition to neuropsychological test-
ing [15]. We also suggest that the definition of abnorm-
ality in neurocognitive performance of asymptomatic
HIV-infected patients without neurocognitive com-
plaints should be modified, for example by changing the
cut-off of individual tests or preferably the mean domain
performance to below 1.5 SD to lower the false-positive
rate.
Figure 1 Probability of a normal control to be categorized as
abnormal according to the criteria of asymptomatic
neurocognitive impairment (ANI) and minor neurocognitive
disorder (MND) if five cognitive domains are tested. Defined as
impairment in functioning, involving at least two ability domains,
documented by performance of at least 1.0 SD below the mean for
norms in one test per domain (blue solid line), in two tests per
domain (blue dotted line) or of at least 1.5 SD below mean for
norms in one test per domain (red line). The probability is plotted
as a function of the degree of correlation between test results of
different cognitive domains with using 0.8 as correlation between
tests in the same domain.
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This is not simply a theoretical issue, but one that has
important therapeutic implications. If one is to target
continued persistent neurological impairment, it is criti-
cal to first define whether the impairment is indeed gen-
uine and not just part of a more than 16% false-positive
rate consequent to the nature of the definition involving
1 SD as cut off in neuropsychological testing, and then
to separate active indolent injury from past injury.
Summary
The diagnoses of less severe forms of HAND relies on
the outcomes of neuropsychological testing, and a high
proportion of HIV-infected patients with effective cART
may be classified as neurocognitively abnormal using
the current criteria. The definition of ANI is not strin-
gent, and results in between 16 and 21% of the popula-
tion being classified as abnormal. To us this seems an
unacceptable false-positive rate.
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